Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)
✉ Email this page to a colleague
TAKEDA PHARMACEUTICAL COMPANY LIMITED v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-02-11 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-07-26 |
| Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | Defendant | Referred To | Tonianne J. Bongiovanni |
| Patents | 6,328,994; 7,399,485; 7,431,942; 7,875,292 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in TAKEDA PHARMACEUTICAL COMPANY LIMITED v. ZYDUS PHARMACEUTICALS (USA) INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-02-11 | 1 | .S. Patent No. 6,328,994 (“’994 Patent”), U.S. Patent No. 7,431,942 (“’942 Patent”), U.S. Patent No. …of the ’994 Patent, ’942 Patent, ’485 Patent, and U.S. Patent No. 5,463,632 (“ ’632 Patent”) would be … (“’292 Patent”), and U.S. Patent No. 7,399,485 (“’485 Patent”) (collectively, “the patents-in- suit…enforceable claim of the ’994 Patent, ’942 Patent, ’292 Patent, or ’485 Patent will be infringed by the …Defendants for infringement of the ’994 Patent, ’942 Patent, and ’632 Patent, based, inter alia, upon Zydus’ | External link to document | |
| 2021-07-26 | 168 | Opinion | U.S. Patent Nos. 6,328,994 (“’994 patent”), issued on December 11, 2001, 7,431,942 (“’942 patent”), issued…wants to market a patented drug prior to the expiration of the patent, the patent owner can seek to… 5,464,632 (“’632 patent”), issued on January 25, 2011, and 7,399,485 (“’485 patent”), issued on July…Claim 1 of the ’994 patent is incorporated as a continuing reference in the other patents, and describes …sustained-release agent.” ’994 patent, col. 37 II. 43-53. All but the ’485 patent expired on May 17, 2019. | External link to document |
| 2018-12-18 | 72 | (the “‘994 Patent”); (b) U.S. Patent No. 7,431,942 (the “‘942 Patent”); (c) U.S. Patent Number No. 7,875,292…‘292 Patent”); and (d) U.S. Patent No. 7,399,485 (the “‘485 Patent”) (collectively, the “patents-in-suit…directly infringed the ‘994 Patent, ‘942 Patent, ‘292 Patent, and ‘485 Patent by filing amended ANDA No…following patents which claim the formulation for the drug Prevacid® SoluTab™: (a) U.S. Patent No. 6,328,994…Zydus, alleging infringement of the ‘994 Patent and ‘992 Patent. Id. ¶ 39; see Takeda Pharm. Co. v. Zydus | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
